US EditionCommon antidepressant can treat long COVID fatigue symptoms: study
Fluvoxamine improved fatigue and quality of life for adults with long COVID with a 99% probability of superiority, while metformin showed no benefit in the REVIVE-TOGETHER trial.
- On Tuesday, a McMaster University-led global team published findings in the Annals of Internal Medicine showing fluvoxamine significantly reduces fatigue in adults with long COVID.
- The REVIVE-TOGETHER trial enrolled 399 adults in Brazil, using a sophisticated adaptive design to compare fluvoxamine, metformin, and placebo over 60 days under researcher Gilmar Reis.
- Evidence suggests a 99% probability fluvoxamine outperformed placebo in reducing fatigue, with recovery 48% more likely at day 30; metformin showed no meaningful benefit.
- Senior author Edward Mills of McMaster University called the findings "an important step forward for patients," citing the drug's established safety profile and immediate clinical potential.
- Researchers caution that findings require replication in broader groups, noting limitations: self-reported outcomes and exclusion of patients with anxiety or depressive disorders.
8 Articles
8 Articles
Antidepressant fluvoxamine reduces long COVID fatigue in clinical trial
A randomized placebo-controlled trial found that fluvoxamine, a low-cost antidepressant, reduced fatigue and improved quality of life in adults with long COVID, offering one of the first evidence-based medication options for this persistent condition. In contrast, metformin did not provide meaningful benefit for established long COVID fatigue, highlighting fluvoxamine as the more promising treatment candidate in this study.
According to a study, mood brighteners could act against the long-term consequences of a corona infection. The symptoms of a fatigue are at least alleviated by the medications.
One Drug Wins and Another Fails for Long COVID Fatigue
(MedPage Today) -- The antidepressant fluvoxamine delivered clinically relevant reductions in long COVID fatigue, but the diabetes drug metformin didn't outdo placebo, according to the randomized REVIVE-TOGETHER trial. Among 399 adults with long...
Vancouver – The antidepressant fluvoxamine may alleviate fatigue symptoms in people with long COVID-19. This was shown in a randomized controlled trial (Annals of Internal Medicine 2026, DOI: 10.7326/ANNALS-25-03959). The antidiabetic drug metformin, on the other hand, had no effect. Currently, there are no medications that can alleviate post-acute...
expert reaction to study looking at fluvoxamine (an antidepressant), metformin, and long COVID fatigue
A study published in the Annals of Internal Medicine looks at the antidepressant fluvoxamine and metformin for fatigue in patients with Long Covid. Prof Christiaan Vinkers, Psychiatrist and Stress & Resilience chair, Amsterdam University Medical Centre, said: “This randomized placebo-controlled trial provides encouraging evidence that fluvoxamine may reduce fatigue in a selected group of patients with long COVID. The study appears methodolog…
Coverage Details
Bias Distribution
- 80% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
